Journal
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
Volume 102, Issue -, Pages 389-391Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.ijid.2020.10.080
Keywords
Hydroxychloroquine; COVID-19; Predictors; QT prolongation; Cardiac events
Categories
Ask authors/readers for more resources
This study aimed to describe QTc prolongation and related adverse cardiac events during the treatment of COVID-19 with HCQ. Critical QTc prolongation was detected in 12% of patients, and diabetes mellitus and the use of oseltamivir were found to be associated with this complication.
The aim of this study was to describe the QTc prolongation and related adverse cardiac events during the administration of hydroxychloroquine (HCQ) and its combinations for the treatment of coronavirus disease 2019 (COVID-19). Hospitalized patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) who received HCQ and had initial and follow-up electrocardiograms performed between March 10 and May 30, 2020 were included. Critical QTc prolongation was detected in 12% of the patients. On multivariate analysis, diabetes mellitus (odds ratio 5.8, 95% confidence interval 1.11-30.32, p = 0.037) and the use of oseltamivir (odds ratio 5.3, 95% confidence interval 1.02-28, p = 0.047) were found to be associated with critical QTc prolongation. (C) 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available